Eaton Vance Management’s BeOne Medicines Ltd ONC Stock Holding History

Eaton Vance Management’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,091	Closed	-$338K	–	1574
2022 Q2	$338K	Buy	+2,091	New	+$327K	﹤0.01%	1446
2022 Q1	–	Sell	-2	Closed	-$1K	–	2772
2021 Q4	$1K	Buy	+2	New	+$675	﹤0.01%	2803
2021 Q3	–	Sell	-789	Closed	-$270K	–	2760
2021 Q2	$270K	Buy	789 +229	+41%	+$75.9K	﹤0.01%	1512
2021 Q1	$194K	Buy	+560	New	+$185K	﹤0.01%	1461

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Eaton Vance Management's ONC Position: Q3 2022 in Review

Eaton Vance Management sold out of BeOne Medicines Ltd (ONC) in Q3 2022, closing a stake of 2,091 shares — an estimated $338K sold.

Eaton Vance Management first reported a position in ONC in Q1 2021 and held it in 4 quarters. The position peaked at $338K in Q2 2022. 223 funds tracked by Wall St. Rank hold ONC as of Q3 2022.

Eaton Vance Management reported no remaining BeOne Medicines Ltd position as of Q3 2022 after selling out during the quarter.
Eaton Vance Management sold 2,091 BeOne Medicines Ltd shares in Q3 2022, an estimated $338K.
Eaton Vance Management first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's BeOne Medicines Ltd position peaked at $338K in Q2 2022.
223 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.